DHEA (dehydroepiandrosterone) is the most abundant adrenal hormone in the human body and a precursor to both testosterone and estrogen. It peaks in the mid-20s and declines progressively with age, falling by approximately 80% between ages 25 and 75. Because it is a precursor to sex hormones, and because those hormones decline at menopause, DHEA supplementation has been studied as a menopause management strategy. One FDA-approved vaginal DHEA product (prasterone/Intrarosa) exists specifically for genitourinary symptoms, while oral DHEA supplementation remains off-label.

The FDA-Approved Application: Intrarosa for GSM

The FDA approved prasterone (Intrarosa) in November 2016 for the treatment of dyspareunia (painful sex) due to vulvar and vaginal atrophy from menopause. It is administered as a vaginal insert (6.5 mg DHEA) once daily at bedtime.

DHEA in vaginal tissue is converted locally to both estrogen and testosterone, which maintain vaginal tissue integrity, lubrication, and elasticity. Because the conversion is primarily local, systemic blood levels of DHEA, estrogen, and testosterone remain within normal postmenopausal ranges. This distinguishes vaginal DHEA from systemic estrogen for women who cannot or prefer not to use systemic hormones.

Clinical trials for Intrarosa found statistically significant improvements in vaginal dryness, dyspareunia, and cell maturation compared to placebo. The effect size is comparable to low-dose vaginal estrogen.

Oral DHEA Supplementation: What the Trials Show

Oral DHEA is available without prescription in the United States as a dietary supplement, which means it is not subject to FDA efficacy review. It is prescription-only in many other countries. The clinical trial evidence for oral DHEA in women is mixed.

Sexual function and mood: A one-year randomized controlled trial in postmenopausal women found that oral DHEA 50 mg daily produced modest improvements in sexual interest and pleasure and reduced depression scores. Not all studies confirm this finding, and the effect sizes are generally small.

Bone density: Some trials show that DHEA supplementation reduces bone turnover markers in postmenopausal women, though the effect on fracture risk has not been demonstrated.

Body composition: Limited evidence suggests DHEA supplementation may modestly reduce fat mass and preserve lean mass in older women, potentially through conversion to testosterone. The effects are not large enough to be clinically significant in most studies.

Cognition: The evidence that DHEA improves cognitive function in postmenopausal women is weak and inconsistent. Well-designed trials have generally not confirmed the cognitive benefits suggested by earlier observational studies.

Dose and Safety of Oral DHEA

Typical doses studied in clinical trials for postmenopausal women: 25-50 mg daily. Doses above 50 mg raise serum DHEA substantially above age-normal levels and increase the risk of androgenic side effects.

Side effects of oral DHEA supplementation in women:

  • Acne (from conversion to testosterone in the skin)
  • Oily skin and scalp
  • Facial hair growth (hirsutism), more common at higher doses
  • Hair loss in women susceptible to androgenetic alopecia

These side effects reflect excessive testosterone conversion and are dose-dependent. Women with PCOS or a history of androgenic symptoms are at higher risk.

Estrogenic effects: DHEA also converts to estrogen. Women with estrogen-sensitive conditions (including estrogen-receptor positive breast cancer history) should discuss DHEA supplementation with their oncologist before using it.

Why DHEA Supplementation Is Complex

Unlike testosterone or estrogen, DHEA converts to different hormones in different tissues at different ratios depending on local enzyme activity. The effect of oral DHEA supplementation is therefore less predictable than supplementing a specific hormone directly. The same 50 mg dose may produce different estrogen-to-testosterone ratios in different women based on their enzyme expression.

This unpredictability is one reason that vaginal DHEA (Intrarosa), where the conversion is localized to the target tissue, has a clearer evidence base than oral DHEA.

For perimenopause and menopause management options, see Perimenopause Symptoms: What Changes, When, and Why and Hormone Replacement Therapy for Women: What the Current Evidence Shows.